<DOC>
	<DOCNO>NCT01989624</DOCNO>
	<brief_summary>Few data currently available literature pancreatic adenocarcinoma France . About 8,000 new case year France . The 5-year survival stage combine &lt; 5 % . This digestive cancer mortality / incidence ratio 98 % . Epidemiological characteristic diagnosis , impact survival recent advance relate surgery , adjuvant chemotherapy new standard form adjuvant chemotherapy ( FOLFIRINOX ) mispriced real life . The development new drug development Phase II III require good understand state disease country . The main objective describe characteristic pancreatic adenocarcinoma diagnosis France make inventory diagnostic practice support .</brief_summary>
	<brief_title>PAncreatic Adenocarcinoma Hospital</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Living France Pancreatic adenocarcinoma histologically cytologically proven primary diagnosis Agreed participate Suspected pancreatic adenocarcinoma histologically cytologically unproven Refused participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pancreatic adenocarcinoma</keyword>
	<keyword>diagnosis</keyword>
	<keyword>treatment</keyword>
</DOC>